Branded

Focus On: Upsher-Smith builds business with focus on novelty, quality

As it moves into its second century in business, Upsher-Smith Labs is focusing on innovating and growing its product offerings while maintaining its high standards.

Neurelis launches Valtoco

Neurelis’ Valtoco is the first and only nasal spray treatment for seizure cluster rescue in adult and pediatric patients age 6 years old and older.

The words approved in caps and red letters.

FDA approves Lundbeck’s Vyepti

Lundbeck’s Vyepti is the first and only intravenous preventive treatment for migraine.

Biohaven gets FDA nod for Nurtec ODT

Biohaven's Nurtec ODT is a single quick-dissolving oral tablet for adult patients with acute migraine.

Seqirus gets FDA nod for Fluad

Seqirus' Fluad Quadrivalent vaccine offers flu protection for adults 65 years old and older.

Sun Pharma introduces Riomet ER

Sun Pharma’s Riomet ER is the first and only liquid formulation of metformin for Type 2 diabetes patients.

Sanofi-Aventis gets FDA OK for Sarclisa

Sanofi-Aventis' Sarclisa works by helping certain cells in the immune system attack multiple myeloma cancer cells.

FDA clears 1st treatment for peanut allergy in children

The FDA has approved Palforzia, the first treatment for peanut allergy in children.

Sun Pharma rolls out Absorica LD

Sun Pharma's Absorica LD features a special formulation of active ingredient isotretinoin meant to optimize absorption at a 20% lower dose.

Allergan launches Ubrelvy

Allergan is offering Ubrelvy for the acute treatment of migraine with or without aura in adults.

FDA approves Eagle's Pemfexy

Eagle has exclusive rights to commercialize Pemfexy for four months beginning Feb. 1, 2022, with an uncapped entry into the market expected on April 1, 2022.

Fresenius Kabi introduces Glucagon Emergency Kit

Fresenius Kabi's glucagon emergency kit provides a treatment for severe hypoglycemia in pediatric and adult patients with diabetes.

FDA approves Teva's Ajovy auto-injector device

Ajovy offers patients the flexibility of quarterly 675 mg or monthly 225 mg dosing options.

FDA approves diazepam nasal spray Valtoco

Valtoco is the first nasal spray approved by the Food and Drug Administration as a rescue treatment for people with epilepsy age 6 years old and older.